BroadOak Funds and Director Snider Disclose 15.97% Stake via Convertible Debt and Warrants, Securing Company Financing

summarizeSummary

BroadOak Funds and Director William Snider have disclosed a 15.97% beneficial ownership stake in Harvard Bioscience, stemming from a $40.0 million debt refinancing package that includes convertible debt and warrants, and also includes recent open-market purchases by the director.

check_boxKey Events

• Significant Beneficial Ownership Disclosed

  BroadOak Funds and Director William Snider collectively beneficially own 846,000 shares, representing 15.97% of Harvard Bioscience's common stock, following a 10:1 reverse stock split on March 13, 2026.

• Debt Refinancing with Convertible Features

  The ownership stems from a $40.0 million Loan and Security Agreement entered into on December 17, 2025. This includes a $7.5 million convertible term loan (conversion price $10.00/share) and warrants to purchase 200,000 shares (exercise price $5.00/share), representing over 21% potential dilution.

• Board Representation Secured

  As part of the loan agreement, William Snider, a partner at BroadOak Capital Partners, was appointed to the Issuer's board of directors and compensation committee, effective December 17, 2025.

• Director Open Market Purchases

  Director William Snider purchased 21,000 shares of common stock in open-market transactions on March 16 and 17, 2026, for a total of approximately $118,564.

auto_awesomeAnalysis

This Schedule 13D filing details a critical financing event for Harvard Bioscience, which the company's recent 10-K indicated alleviated going concern doubts. BroadOak Funds and Director William Snider have disclosed a significant 15.97% beneficial ownership stake, primarily through a $40.0 million loan agreement from December 2025. This financing included a $7.5 million convertible loan and warrants, which introduce substantial potential dilution of over 21% if fully converted and exercised. While the financing provides essential capital for debt repayment and working capital, the terms are costly. The appointment of William Snider to the board as part of this agreement signifies active investor involvement. Furthermore, Snider's recent open-market purchases of approximately $118,564 in company stock demonstrate a vote of confidence following the company's recent negative earnings report and reverse stock split.